Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Files Universal Shelf Registration
Apr 17, 2006
|
64.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 17, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission. Upon being declared effective by the SEC, the shelf registration s...
|
|
|
Corgentech to Present at CIBC World Markets' Annual Biotechnology and Specialty Pharmaceuticals Conference 2006
Mar 27, 2006
|
68.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's chief executive officer, will present at CIBC World Markets' Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 4,...
|
|
|
Corgentech Reports Phase 2 Trial Results for 4975 in Hernia Repair Pain
Mar 24, 2006
|
72.3 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today reported clinical results from a Phase 2 trial of 4975, the company's novel, long-acting, non-opioid drug candidate being developed in multiple mid-stage clinical trials for site-specific, moderate to severe pain.
...
|
|
|
Corgentech Phase 2 Trial of ALGRX 4975 Meets Primary Endpoint of Decreased Pain for Tendonitis Patients
Mar 9, 2006
|
75.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 9, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today reported positive clinical data from a Phase 2 clinical trial showing that ALGRX 4975-one of three non-opioid pain management drug candidates the company is developing-demonstrated sustained, statistically significant p...
|
|
|
Corgentech Presents Clinical Data From Phase 1/2 Trial of Avrina(TM), Drug Candidate for Eczema
Mar 6, 2006
|
72.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 6, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today presented clinical data from one of two Phase 1/2 clinical trials of Avrina, Corgentech's NF-kappaB Decoy drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema that affects a...
|
|
|
Click here to download our most recent fact sheet.